TABLE 7.
Cost‐effectiveness of treatment strategies for hepatitis C virus infection among kidney waitlist candidates
| Treatment strategy | Cost, $ | Incremental cost, $ |
QALM | Incremental QALM |
ICER, $/QALY | Undiscounted life months |
|---|---|---|---|---|---|---|
| Overall (3% annual dialysis mortality) | ||||||
| Treat posttransplant | 808 200 | 75.4 | 208.3 | |||
| Treat pretransplant | 885 100 | 76 900 | 81.3 | 5.9 | 155 600 | 211.3 |
| Overall (6% annual dialysis mortality) | ||||||
| Treat posttransplant | 682 400 | 61.8 | 164.8 | |||
| Treat pretransplant | 735 700 | 53 300 | 65.6 | 3.9 | 162 800 | 164.5 |
| Overall (12% annual dialysis mortality) | ||||||
| Treat posttransplant | 509 700 | 42.8 | 109.3 | |||
| Treat pretransplant | 541 900 | 32 100 | 44.8 | 2.1 | 188 000 | 107.3 |
| Overall (18% annual dialysis mortality) | ||||||
| Treat posttransplant | 400 700 | 31.1 | 77.0 | |||
| Treat pretransplant | 424 444 | 23 900 | 32.3 | 1.2 | 242 600 | 74.6 |
| Overall (24% annual dialysis mortality) | ||||||
| Treat posttransplant | 325 400 | 23.4 | 56.8 | |||
| Treat pretransplant | 345 700 | 20 300 | 24.2 | 0.8 | 303 800 | 54.9 |
QALM, quality‐adjusted life month; ICER, incremental cost‐effectiveness ratio; QALY, quality‐adjusted life years.